The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | Impact of prior tafasitamab treatment on subsequent CD19-directed CAR-T therapy
Reona Sakemura, MD, PhD, Mayo Clinic, Rochester, MN, talks on the results of a study investigating the impact of prior CD19-targeting monoclonal antibody treatment with tafasitamab on subsequent treatment with CD19-directed CAR-T therapy. The study reported that prior tafasitamab treatment resulted in delayed CAR-T expansion and reduced CAR-T apoptosis in mouse models, and suggested that sequential therapy may reduce CAR-T toxicity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
